Founded just five years ago, the Luxembourg Pharmaceutical Association (APL) was created in response to the divergence of Luxembourg’s pharmaceutical regulatory environment with Belgium. At present, Secretary General Hendrik Kühne’s primary objective is to build a stronger dialogue and greater trust with the authorities, such that the industry can be involved in discussions regarding new regulations or policies prior to their enactment. The Luxembourg Pharmaceutical Association (APL), established in 2011, is certainly one of the youngest innovative pharmaceutical associations in Europe. Why, after many years without a pharmaceutical association, was the APL eventually created?
"Pharmaceutical companies are viewed quite positively [in Luxembourg], and the government is very open to dialogue with the pharmaceutical industry, particularly in terms of attracting research activities and investments."